|
MechanismTop II inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Jul 1992 |
100 Clinical Results associated with HQ Specialty Pharma
0 Patents (Medical) associated with HQ Specialty Pharma
100 Deals associated with HQ Specialty Pharma
100 Translational Medicine associated with HQ Specialty Pharma